BERGAMASCHI, MICAELA
 Distribuzione geografica
Continente #
EU - Europa 1.735
AS - Asia 224
NA - Nord America 94
SA - Sud America 13
AF - Africa 3
Totale 2.069
Nazione #
IT - Italia 1.705
SG - Singapore 98
US - Stati Uniti d'America 86
VN - Vietnam 63
CN - Cina 48
FR - Francia 15
BR - Brasile 7
FI - Finlandia 6
CA - Canada 4
AR - Argentina 3
HK - Hong Kong 3
IN - India 3
MX - Messico 3
BD - Bangladesh 2
CH - Svizzera 2
GB - Regno Unito 2
MA - Marocco 2
NL - Olanda 2
CL - Cile 1
CO - Colombia 1
ID - Indonesia 1
IQ - Iraq 1
JM - Giamaica 1
KE - Kenya 1
LK - Sri Lanka 1
LT - Lituania 1
MT - Malta 1
PH - Filippine 1
PK - Pakistan 1
PS - Palestinian Territory 1
PY - Paraguay 1
SE - Svezia 1
TR - Turchia 1
Totale 2.069
Città #
Genova 879
Genoa 507
Rapallo 180
Vado Ligure 130
Singapore 52
San Jose 27
Ashburn 21
Hanoi 19
Lauterbourg 14
Ho Chi Minh City 13
Beijing 7
Helsinki 6
New York 6
Haiphong 5
Council Bluffs 4
Los Angeles 4
Da Nang 3
Montreal 3
Shanghai 3
Amsterdam 2
Bordighera 2
Hong Kong 2
Pesaro 2
São Paulo 2
Albuquerque 1
Ankara 1
Atlanta 1
Baghdad 1
Barranquilla 1
Belo Horizonte 1
Biên Hòa 1
Brooklyn 1
Buffalo 1
Bắc Ninh 1
Chapada Gaúcha 1
Chicago 1
Ciudad del Este 1
Colombo 1
Corrientes 1
Cuautitlán Izcalli 1
Dallas 1
Denver 1
Des Moines 1
Elizabeth 1
Erebango 1
Fatehgarh 1
Fredericksburg 1
General Roca 1
Isidro Casanova 1
Islamabad 1
Kochi 1
Long Xuyen 1
Maceió 1
Marrakesh 1
Marseille 1
Martinez 1
Monterrey 1
Nairobi 1
Naples 1
New Delhi 1
Newark 1
Nha Trang 1
Ninh Bình 1
Orem 1
Québec 1
Quận Ba 1
Quận Bình Thạnh 1
Quận Bốn 1
Rome 1
Santa Clara 1
Santiago 1
Sioux Falls 1
Stockholm 1
Suzhou 1
Taroudant 1
Tijuana 1
Uberaba 1
Valletta 1
Zumpano 1
Zurich 1
Totale 1.949
Nome #
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 258
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 240
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 168
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 167
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 159
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 152
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 149
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 136
Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. 131
Un cas de cryptococcose cutanèe primitive sans diffusion systemique chez un patient immunodeprimé 125
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 99
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 97
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 96
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 90
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 76
Totale 2.143
Categoria #
all - tutte 7.506
article - articoli 7.110
book - libri 0
conference - conferenze 396
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.012


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202154 0 0 0 0 0 0 0 0 0 33 14 7
2021/2022179 8 2 5 22 3 14 3 38 18 12 12 42
2022/2023217 21 25 3 24 35 36 0 18 31 3 20 1
2023/2024115 10 10 3 19 10 22 5 14 3 1 2 16
2024/2025361 12 18 8 26 35 43 33 91 7 18 33 37
2025/2026506 75 15 27 26 100 38 100 27 45 53 0 0
Totale 2.143